Biogen and Denali Therapeutics have discontinued development of BIIB122 for early-stage Parkinson's disease. The decision follows Phase 2b LUMA trial results, where BIIB122 did not meet efficacy ...
UCB and Biogen ( BIIB) on Monday said that their investigational drug dapirolizumab pegol met the primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a ...
Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing ...
Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant ...
Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing ...
Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle ...
Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over ...
MILAN, May 27 (Reuters) - Italy's antitrust authority (AGCM) said on Wednesday it had opened an investigation into Biogen ...
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the ...
Biogen Inc. said it will continue development of its experimental Alzheimer’s drug after getting promising though not definitive signs of benefit in a mid-stage study, offering hope for a new approach ...
Check out the companies making the biggest moves in premarket trading: Biogen — Shares advanced 4% after the biopharmaceutical company announced its experimental Alzheimer's drug will advance into a ...
Biogen axed an Ionis-partnered antisense oligonucleotide that targets LRRK2 last year. Other biotechs continue to work on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results